EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Xpert MTB/RIF Ultra-resistant and MTBDR plus- susceptible rifampicin results in people with tuberculosis: utility of FluoroType MTBDR and deep sequencing

Yonas Ghebrekristos, Aysha Ahmed, Natalie Beylis, Sarishna Singh, Christoffel Opperman iD, Fahd Naufal, Megan Folkerts, David Engelthaler iD, Erick Auma, Rouxjeane Venter, Ghowa Booley, John Metcalfe und 2 weitere

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01671-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Yonas Ghebrekristos und 13 weiteren Autor:innen. Beteiligte Einrichtung: DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Huma…. Hauptthemen laut MEDLINE: Rifampin, Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant, Antitubercular Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership (EDCTP), NIBIB NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Xpert MTB/RIF Ultra (Ultra)-detected rifampicin-resistant tuberculosis (TB) is often programmatically confirmed using MTBDR plus . There are limited data on discordant results, including when re-tested using newer methods, like FluoroType MTBDR (FT-MTBDR) and targeted deep sequencing. MTBDR plus rifampicin-susceptible isolates from people with Ultra rifampicin-resistant sputum were identified from a South African programmatic laboratory. FT-MTBDR and single molecule-overlapping reads (SMOR; rpoB , inhA , katG ) on isolate DNA were done (SMOR was used as a reference standard). Between 1 April 2021 and 30 September 2022, 8% (109/1347) of Ultra rifampicin-resistant specimens were MTBDR plus -susceptible. Of 89% (97/109) isolates with a sequenceable rpoB , SMOR resolved most in favor of Ultra (79% [77/97]). Sputum with lower mycobacterial load was associated with Ultra false-positive resistance (46% [11/24] of “very low” Ultra had false resistance vs 12% [9/73; P = 0.0004] of ≥“low”), as were Ultra heteroresistance calls (all wild-type probes, ≥1 mutant probe) (62% [23/37 vs 25% 15/60] for Ultra without heteroresistance calls; P = 0.0003). Of the 91% (88/97) of isolates successfully tested by FT-MTBDR, 55% (48/88) were FT-MTBDR rifampicin-resistant and 45% (40/88) susceptible, translating to 69% (47/68) sensitivity and 95% (19/20) specificity. In the 91% (99/109) of isolates with inhA and katG sequenced, 62% (61/99) were SMOR isoniazid-susceptible. When Ultra and MTBDR plus rifampicin results are discordant, Ultra is more likely to be correct, and FT-MTBDR agrees more with Ultra than MTBDR plus ; however, lower load and the Ultra heteroresistance probe pattern were risk factors for Ultra false rifampicin-resistant results. Most people with Ultra–MTBDR plus discordant resistance results were isoniazid-susceptible. These data have implications for drug-resistant TB diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsHumansHigh-Throughput Nucleotide SequencingMicrobial Sensitivity TestsSputumBacterial ProteinsDNA-Directed RNA PolymerasesSouth AfricaCatalaseDrug Resistance, BacterialOxidoreductases

Stichwörter der Autor:innen

diagnosisheteroresistancerifampicin susceptibilitytuberculosis

Substanzen

RifampinBacterial ProteinsAntitubercular AgentsrpoB protein, Mycobacterium tuberculosisDNA-Directed RNA PolymerasesCatalaseInhA protein, MycobacteriumOxidoreductaseskatG protein, Mycobacterium tuberculosis

Autor:innen und Institutionen

  • DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch Univ…
  • National Health Laboratory Service, Greenpoint Tuberculosis Laboratory, Cape Town, South Africa.
  • Division of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • University of California San Francisco, San Francisco, California, USA.
  • Translational Genomics Research Institute, Phoenix, Arizona, USA.

ORCID-Profile: Christoffel Opperman, David Engelthaler, Grant Theron

Förderung

  • NIAID NIH HHS
  • EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership (EDCTP)
  • NIBIB NIH HHS
  • HHS | National Institutes of Health (NIH)
  • FIC NIH HHS

Zitieren

APA

Ghebrekristos, Y., Ahmed, A., Beylis, N., Singh, S., Opperman, C., Naufal, F., Folkerts, M., Engelthaler, D., Auma, E., Venter, R., Booley, G., Metcalfe, J., Warren, R., & Theron, G. (2025). Xpert MTB/RIF Ultra-resistant and MTBDR plus- susceptible rifampicin results in people with tuberculosis: utility of FluoroType MTBDR and deep sequencing. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01671-24

Vancouver

Ghebrekristos Y, Ahmed A, Beylis N, Singh S, Opperman C, Naufal F, et al. Xpert MTB/RIF Ultra-resistant and MTBDR plus- susceptible rifampicin results in people with tuberculosis: utility of FluoroType MTBDR and deep sequencing. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01671-24

BibTeX
@article{Ghebrekristos2025,
  author = {Ghebrekristos, Yonas and Ahmed, Aysha and Beylis, Natalie and Singh, Sarishna and Opperman, Christoffel and Naufal, Fahd and Folkerts, Megan and Engelthaler, David and Auma, Erick and Venter, Rouxjeane and Booley, Ghowa and Metcalfe, John and Warren, Robin and Theron, Grant},
  title = {Xpert MTB/RIF Ultra-resistant and MTBDR plus- susceptible rifampicin results in people with tuberculosis: utility of FluoroType MTBDR and deep sequencing},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01671-24}
}
Kostenlos starten →